Comparison of insulinoma-associated protein 1 (INSM1) with traditional neuroendocrine markers in gastrointestinal and pancreatic mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs).
Humans
Biomarkers, Tumor
/ analysis
Middle Aged
Pancreatic Neoplasms
/ pathology
Female
Male
Aged
Gastrointestinal Neoplasms
/ pathology
Repressor Proteins
/ analysis
Adult
Immunohistochemistry
CD56 Antigen
/ analysis
Synaptophysin
/ analysis
Chromogranin A
/ analysis
Neuroendocrine Tumors
/ pathology
Carcinoma, Neuroendocrine
/ pathology
Sensitivity and Specificity
Aged, 80 and over
Chromogranin A
Insulinoma-associated protein 1
Mixed neuroendocrine-non-neuroendocrine neoplasm
Neuroendocrine carcinoma
Synaptophysin
Journal
Diagnostic pathology
ISSN: 1746-1596
Titre abrégé: Diagn Pathol
Pays: England
ID NLM: 101251558
Informations de publication
Date de publication:
29 Oct 2024
29 Oct 2024
Historique:
received:
08
08
2024
accepted:
24
10
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
epublish
Résumé
The traditional diagnostic markers for mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs) are synaptophysin (SYP), chromogranin A (CHGA) and CD56. However, there is still a lack of a large series of article focused on the expression of insulinoma-associated protein 1 (INSM1) in gastrointestinal and pancreatic MiNENs. This study compared the expression of INSM1 and traditional neuroendocrine markers in MiNENs. In this study, we collected 46 cases of gastrointestinal and pancreatic MiNENs and performed immunohistochemical staining for INSM1, SYP, CHGA, and CD56. Histologically, the neuroendocrine components of MiNENs were all neuroendocrine carcinomas, with small cell neuroendocrine carcinomas accounting for 15.2% (7/46) and large cell neuroendocrine carcinomas accounting for 84.8% (39/46). With respect to immunohistochemical expression, the overall sensitivity of INSM1 was 80.4% (37/46), which was lower than that of SYP (100%, 46/46), but comparable to that of CHGA (67.4%, 31/46) or CD56 (73.9%, 34/46). The overall specificity of INSM1 was 91.3% (42/46), which was greater than that of SYP (63.0%, 29/46) and CD56 (69.6, 32/46), but was not significantly different from that of CHGA (82.6%, 38/46). The proportion of 3 + staining for SYP (100%, 46/46) was greater than that of INSM1 (71.7, 33/46), while the proportion of 3 + staining for CHGA (10.9, 5/46) or CD56 (21.7, 10/46) was lower than that of INSM1. In conclusion, INSM1 exhibited high sensitivity and specificity in the diagnosis of gastrointestinal and pancreatic MiNENs.
Identifiants
pubmed: 39472993
doi: 10.1186/s13000-024-01568-0
pii: 10.1186/s13000-024-01568-0
doi:
Substances chimiques
INSM1 protein, human
147955-03-1
Biomarkers, Tumor
0
Repressor Proteins
0
CD56 Antigen
0
Synaptophysin
0
Chromogranin A
0
NCAM1 protein, human
0
SYP protein, human
0
Types de publication
Journal Article
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
144Subventions
Organisme : Startup Fund for scientific research, Fujian Medical University
ID : 2022QH1288
Informations de copyright
© 2024. The Author(s).
Références
IARC WHO Classification of Tumours. WHO Classification of Tumours. Digestive System Tumours. Fifth Edition—WHO—OMS—(Volume 1) WHO; Lyon, France. (2019).
Frizziero M, Chakrabarty B, Nagy B et al. Mixed Neuroendocrine Non-Neuroendocrine Neoplasms: A Systematic Review of a Controversial and Underestimated Diagnosis. J Clin Med. (2020) Jan 19;9(1):273. https://doi.org/10.3390/jcm9010273
Duggan A, Madathany T, de Castro SC et al. Transient expression of the conserved zinc finger gene INSM1 in progenitors and nascent neurons throughout embryonic and adult neurogenesis. J Comp Neurol. (2008) Apr 1;507(4):1497 – 520. https://doi.org/10.1002/cne.21629
Mukhopadhyay S, Dermawan JK, Lanigan CP, Farver CF. Insulinoma-associated protein 1 (INSM1) is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: an immunohistochemical study of 345 cases, including 292 whole-tissue sections. Mod Pathol. 2019;32(1):100–9. https://doi.org/10.1038/s41379-018-0122-7 .
doi: 10.1038/s41379-018-0122-7
pubmed: 30154579
Fujino K, Motooka Y, Hassan WA, et al. Insulinoma-Associated Protein 1 Is a Crucial Regulator of Neuroendocrine Differentiation in Lung Cancer. Am J Pathol. 2015;185(12):3164–77. https://doi.org/10.1016/j.ajpath.2015.08.018 .
doi: 10.1016/j.ajpath.2015.08.018
pubmed: 26482608
Švajdler M, Mezencev R, Šašková B, et al. Triple marker composed of p16, CD56, and TTF1 shows higher sensitivity than INSM1 for diagnosis of pulmonary small cell carcinoma: proposal for a rational immunohistochemical algorithm for diagnosis of small cell carcinoma in small biopsy and cytology specimens. Hum Pathol. 2019;85:58–64. https://doi.org/10.1016/j.humpath.2018.10.016 .
doi: 10.1016/j.humpath.2018.10.016
pubmed: 30385371
Takase Y, Naito Y, Okabe Y, et al. Insulinoma-associated protein 1 expression in pancreatic neuroendocrine tumours in endoscopic ultrasound-guided fine-needle aspiration cytology: An analysis of 14 patients. Cytopathology. 2019;30(2):194–200. https://doi.org/10.1111/cyt.12640 .
doi: 10.1111/cyt.12640
pubmed: 30290028
Tanigawa M, Nakayama M, Taira T, et al. Insulinoma-associated protein 1 (INSM1) is a useful marker for pancreatic neuroendocrine tumor. Med Mol Morphol. 2018;51(1):32–40. https://doi.org/10.1007/s00795-017-0167-6 .
doi: 10.1007/s00795-017-0167-6
pubmed: 28849340
González I, Lu HC, Sninsky J, et al. Insulinoma-associated protein 1 expression in primary and metastatic neuroendocrine neoplasms of the gastrointestinal and pancreaticobiliary tracts. Histopathology. 2019;75(4):568–77. https://doi.org/10.1111/his.13899 .
doi: 10.1111/his.13899
pubmed: 31077609
Rooper LM, Bishop JA, Westra WH. INSM1 is a Sensitive and Specific Marker of Neuroendocrine Differentiation in Head and Neck Tumors. Am J Surg Pathol. 2018;42(5):665–71. https://doi.org/10.1097/PAS.0000000000001037 .
doi: 10.1097/PAS.0000000000001037
pubmed: 29438167
Lilo MT, Chen Y, LeBlanc RE. INSM1 Is More Sensitive and Interpretable than Conventional Immunohistochemical Stains Used to Diagnose Merkel Cell Carcinoma. Am J Surg Pathol. 2018;42(11):1541–8. https://doi.org/10.1097/PAS.0000000000001136 .
doi: 10.1097/PAS.0000000000001136
pubmed: 30080705
Rush PS, Rosenbaum JN, Roy M, et al. Insulinoma-associated 1: A novel nuclear marker in Merkel cell carcinoma (cutaneous neuroendocrine carcinoma). J Cutan Pathol. 2018;45(2):129–35. https://doi.org/10.1111/cup.13079 .
doi: 10.1111/cup.13079
pubmed: 29148079
Xin Z, Zhang Y, Jiang Z, et al. Insulinoma-associated protein 1 is a novel sensitive and specific marker for small cell carcinoma of the prostate. Hum Pathol. 2018;79:151–9. https://doi.org/10.1016/j.humpath.2018.05.014 .
doi: 10.1016/j.humpath.2018.05.014
pubmed: 29885405
Kuji S, Watanabe R, Sato Y, et al. A new marker, insulinoma-associated protein 1 (INSM1), for high-grade neuroendocrine carcinoma of the uterine cervix: Analysis of 37 cases. Gynecol Oncol. 2017;144(2):384–90. https://doi.org/10.1016/j.ygyno.2016 .
doi: 10.1016/j.ygyno.2016
pubmed: 27908529
McHugh KE, Mukhopadhyay S, Doxtader EE et al. INSM1 Is a Highly Specific Marker of Neuroendocrine Differentiation in Primary Neoplasms of the Gastrointestinal Tract, Appendix, and Pancreas. Am J Clin Pathol. (2020) May 5;153(6):811–820. https://doi.org/10.1093/ajcp/aqaa014
Sakakibara R, Kobayashi M, Takahashi N, et al. Insulinoma-associated Protein 1 (INSM1) Is a Better Marker for the Diagnosis and Prognosis Estimation of Small Cell Lung Carcinoma Than Neuroendocrine Phenotype Markers Such as Chromogranin A, SYPaptophysin, and CD56. Am J Surg Pathol. 2020;44(6):757–64. https://doi.org/10.1097/PAS.0000000000001444 .
doi: 10.1097/PAS.0000000000001444
pubmed: 32118626
Staaf J, Tran L, Söderlund L et al. Diagnostic Value of Insulinoma-Associated Protein 1 (INSM1) and Comparison With Established Neuroendocrine Markers in Pulmonary Cancers. Arch Pathol Lab Med. (2020) Sep 1;144(9):1075–1085. https://doi.org/10.5858/arpa.2019-0250-OA
Rindi G, Mete O, Uccella S et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol. (2022) Mar;33(1):115–154. https://doi.org/10.1007/s12022-022-09708-2
Milione M, Maisonneuve P, Pellegrinelli A, et al. Ki67 proliferative index of the neuroendocrine component drives MANEC prognosis. Endocr Relat Cancer. 2018;25(5):583–93. https://doi.org/10.1530/ERC-17-0557 .
doi: 10.1530/ERC-17-0557
pubmed: 29592868
Frizziero M, Wang X, Chakrabarty B, et al. Mixed adeno-neuroendocrine carcinoma (MANEC) of the gastroenteropancreatic (GEP) tract: A multicentre retrospective study. Ann Oncol. 2017;28. https://doi.org/10.1093/annonc/mdx368 . Suppl. 5).
Fujino K, Yasufuku K, Kudoh S, et al. INSM1 is the best marker for the diagnosis of neuroendocrine tumors: comparison with CHGA, SYP and CD56. Int J Clin Exp Pathol. 2017;10(5):5393–405.
Kim D, Viswanathan K, Goyal A, Rao R. Insulinoma-associated protein 1 (INSM1) is a robust marker for identifying and grading pancreatic neuroendocrine tumors. Cancer Cytopathol. 2020;128(4):269–77. https://doi.org/10.1002/cncy.22242 .
doi: 10.1002/cncy.22242
pubmed: 31977134
Wang J, Wang B, Gou S, et al. Diagnostic value of INSM1 in gastroenteropancreatic neuroendocrine neoplasms. Chin J Clin Exp Pathol. 2019;35:407–11.
Watanabe J, Suwa Y, Ota M, et al. Clinicopathological and Prognostic Evaluations of Mixed Adenoneuroendocrine Carcinoma of the Colon and Rectum: A Case-Matched Study. Dis Colon Rectum. 2016;59(12):1160–7. https://doi.org/10.1097/DCR.0000000000000702 .
doi: 10.1097/DCR.0000000000000702
pubmed: 27824701
Woischke C, Schaaf CW, Yang HM, et al. In-depth mutational analyses of colorectal neuroendocrine carcinomas with adenoma or adenocarcinoma components. Mod Pathol. 2017;30(1):95–103. https://doi.org/10.1038/modpathol.2016.150 .
doi: 10.1038/modpathol.2016.150
pubmed: 27586204
Nie L, Li M, He X et al. Gastric mixed adenoneuroendocrine carcinoma: correlation of histologic characteristics with prognosis. Ann Diagn Pathol (2016) Dec;25:48–53. https://doi.org/10.1016/j.anndiagpath
Carboni F, Valle M, Russo A. Mixed adenoneuroendocrine carcinoma of the cecum. Clin Res Hepatol Gastroenterol. 2019;43(6):627–9. https://doi.org/10.1016/j.clinre.2019.02.002 .
doi: 10.1016/j.clinre.2019.02.002
pubmed: 30853491
Farooq F, Zarrabi K, Sweeney K, et al. Multiregion Comprehensive Genomic Profiling of a Gastric Mixed Neuroendocrine-Nonneuroendocrine Neoplasm with Trilineage Differentiation. J Gastric Cancer. 2018;18(2):200–7. https://doi.org/10.5230/jgc.2018.18.e16 .
doi: 10.5230/jgc.2018.18.e16
pubmed: 29984070
pmcid: 6026709
Chen I, Zhang D, Velez M, et al. Poorly differentiated neuroendocrine carcinomas of the gastrointestinal tract: A single-institute study of 43 cases. Pathol Res Pract. 2021;226:153614. https://doi.org/10.1016/j.prp.2021.153614 .
doi: 10.1016/j.prp.2021.153614
pubmed: 34555651